← Eichor
Study identifier: NCT06790797 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients

Condition: Lung Cancer · Esophageal Cancer  ·  Sponsor: Zhao Jun

PhaseN/A
Planned participants50
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This study aims to investigate the impact of immunotherapy on the immune status of tumor microenvironment and peripheral blood of chest cancer patients. To do so, the investigators plan to collect tumor tissue and peripheral blood samples before and after immunotherapy, and use single-cell RNA sequencing, Multiplex immunohistochemistry, and flow cytometry. The investigators will analyze changes in the proportion of cancer cell-specific T-cell subpopulations related to treatment response before and after therapy, and seek biological markers that can predict the efficacy of immunotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Mi Liu  ·  86-0512-67972216  ·  mi.liu831116@icoud.com

Jun Zhao  ·  86-0512-67972216  ·  zhaojia0327@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

The first affiliated hospital of soochow universitySuzhou, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06790797